1. PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α. (June 2017) Authors: Berinstein, N.; Smyth, L.; Pennell, N.; Weerasinghe, R.; Cheung, M.; Imrie, K.; Spaner, D.; Chodirker, L.; Piliotis, E.; Milliken, V.; Boudreau, A.; Zhang, L.; Reis, M.; Chesney, A.; Good, D.; Ghorab, Z.; Buckstein, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SPIReL: PHASE 2 STUDY DPX‐SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Berinstein, N.L.; Bence‐Buckler, I.A.; Laneuville, P.; Stewart, D.; Smyth, L.; Kerr, C.; Klein, G.; Pennell, N.; Roos‐Assar, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 569 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗